Depression and the link with cardiovascular disease

Frontiers in Psychiatry

Volumn 7, Issue MAR, 2016, Pages 1-

  Dhar, Arup K ^a,b,c   Barton, David A ^a,b,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b Alfred Psychiatry Alfred Health   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Cardiac risk; Cardiovascular disease; Coronary heart disease; Depression; Major depressive disorder

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ALCOHOL CONSUMPTION; ANXIETY; APPETITE DISORDER; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DIZZINESS; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LIFESTYLE; MAJOR DEPRESSION; MENTAL STRESS; NONHUMAN; OBESITY; PHYSICAL INACTIVITY; PLATELET REACTIVITY; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SEXUAL DYSFUNCTION; SLEEP DISORDER; SMOKING; SOCIOECONOMICS; STRESS; SYMPATHETIC TONE; THROMBOCYTE ACTIVATION;

EID: 84982151744     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2016.00033     Document Type: Article

References (121)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: ManMag (2013).
2. Celano CM, Huffman JC. Depression and cardiac disease: a review. Cardiol Rev (2011) 19:130-42. doi: 10.1097/CRD.0b013e31820e8106
3. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil (2009) 16:121-37. doi:10.1097/HJR.0b013e3283294b1d
4. Carney RM, Blumenthal JA, Freedland KE, Youngblood M, Veith RC, Burg MM, et al. Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosom Med (2004) 66:466-74. doi:10.1097/01.psy.0000133362.75075.a6
5. Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res (2002) 53:849-57. doi:10.1016/S0022-3999(02)00304-5
6. Brown AD, Barton DA, Lambert GW. Cardiovascular abnormalities in patients with major depressive disorder. CNS Drugs (2009) 23:583-602. doi:10.2165/00023210-200923070-00004
7. Carney RM, Rich MW, Freedland KE, Saini J, Simeone C, Clark K. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med (1988) 50:627-33. doi:10.1097/00006842-198811000-00009
8. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation (1996) 93:1976-80. doi:10.1161/01.CIR.93.11.1976
9. Ziegelstein RC. Depression in patients recovering from a myocardial infarction. JAMA (2001) 286:1621-7. doi:10.1001/jama.286.13.1621
10. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry (1998) 55:580-92. doi:10.1001/archpsyc.55.7.580
11. Bunker SJ, Colquhoun DM, Esler MD, Hickie IB, Hunt D, Jelinek VM, et al. "Stress" and coronary heart disease: psychosocial risk factors. Med J Aust (2003) 178:272-6.
12. Rosengren A, Hawken S, ôunpuu S, Sliwa K, Zubaid M, Almahmeed WA, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study. Lancet (2004) 364:953-62. doi:10.1016/S0140-6736(04)17019-0
13. Baumeister H, Balke K, Härter M. Psychiatric and somatic comorbidities are negatively associated with quality of life in physically ill patients. J Clin Epidemiol (2005) 58:1090-100. doi:10.1016/j.jclinepi.2005.03.011
14. Rugulies R. Depression as a predictor for coronary heart disease: a review and meta-analysis. Am J Prev Med (2002) 23:51-61. doi:10.1016/S0749-3797(02)00439-7
15. Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosom Med (2003) 65:201-10. doi:10.1097/01.PSY.0000058371.50240.E3
16. Van Der Kooy K, Van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. Depression and the risk for cardiovascular diseases: systematic review and meta analysis. Int J Geriatr Psychiatry (2007) 22:613-26. doi:10.1002/gps.1723
17. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med (2004) 66:802-13. doi:10.1097/01.psy.0000146332.53619.b2
18. Frasure-Smith N, Lespérance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation (1995) 91:999-1005. doi:10.1161/01.CIR.91.4.999
19. Katon WJ, Lin EH, Russo J, Von Korff M, Ciechanowski P, Simon G, et al. Cardiac risk factors in patients with diabetes mellitus and major depression. J Gen Intern Med (2004) 19:1192-9. doi:10.1111/j.1525-1497.2004.30405.x
20. Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry (1998) 155(1):4-11. doi:10.1176/ajp.155.1.4
21. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J (2006) 27:2763-74. doi:10.1093/eurheartj/ehl338
22. Lange-Asschenfeldt C, Lederbogen F. [Antidepressant therapy in coronary artery disease]. Nervenarzt (2011) 82:657-64. doi:10.1007/s00115-010-3181-7
23. Esler M, Turbott J, Schwarz R, Leonard P, Bobik A, Skews H, et al. The peripheral kinetics of norepinephrine in depressive illness. Arch Gen Psychiatry (1982) 39:295-300. doi:10.1001/archpsyc.1982.04290030035006
24. Veith RC, Lewis N, Linares OA, Barnes RF, Raskind MA, Villacres EC, et al. Sympathetic nervous system activity in major depression: basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry (1994) 51:411-22. doi:10.1001/archpsyc.1994.03950050071008
25. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation (2003) 108:560-5. doi:10.1161/01.CIR.0000081775.72651.B6
26. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol (1993) 22:S1-4. doi:10.1097/00005344-199322004-00002
27. Ghiadoni L, Donald AE, Cropley M, Mullen MJ, Oakley G, Taylor M, et al. Mental stress induces transient endothelial dysfunction in humans. Circulation (2000) 102:2473-8. doi:10.1161/01.CIR.102.20.2473
28. Spieker LE, Hürlimann D, Ruschitzka F, Corti R, Enseleit F, Shaw S, et al. Mental stress induces prolonged endothelial dysfunction via endothelin-A receptors. Circulation (2002) 105:2817-20. doi:10.1161/01.CIR.0000021598.15895.34
29. Brydon L, Edwards S, Jia H, Mohamed-Ali V, Zachary I, Martin JF, et al. Psychological stress activates interleukin-1ß gene expression in human mononuclear cells. Brain Behav Immun (2005) 19:540-6. doi:10.1016/j.bbi.2004.12.003
30. von Känel R, Kudielka BM, Preckel D, Hanebuth D, Fischer JE. Delayed response and lack of habituation in plasma interleukin-6 to acute mental stress in men. Brain Behav Immun (2006) 20:40-8. doi:10.1016/j.bbi.2005.03.013
31. Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med (1991) 325:618-24. doi:10.1056/NEJM199108293250905
32. Wittstein IS, Thiemann DR, Lima JA, Baughman KL, Schulman SP, Gerstenblith G, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med (2005) 352:539-48. doi:10.1056/NEJMoa043046
33. Stapelberg NJ, Neumann DL, Shum DH, Mcconnell H, Hamilton-Craig I. A topographical map of the causal network of mechanisms underlying the relationship between major depressive disorder and coronary heart disease. Aust N Z J Psychiatry (2011) 45:351-69. doi:10.3109/00048674.2011.570427
34. Carney RM, Saunders RD, Freedland KE, Stein P, Rich MW, Jaffe AS. Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol (1995) 76:562-4. doi:10.1016/S0002-9149(99)80155-6
35. Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, et al. Sympathetic augmentation in hypertension role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension (2004) 43:169-75. doi:10.1161/01.HYP.0000103160.35395.9E
36. Dinan TG. Glucocorticoids and the genesis of depressive illness. A psychobiological model. Br J Psychiatry (1994) 164:365-71. doi:10.1192/bjp.164.3.365
37. Wong M-L, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P, et al. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci U S A (2000) 97:325-30. doi:10.1073/pnas.97.1.325
38. Barton DA, Dawood T, Lambert EA, Esler MD, Haikerwal D, Brenchley C, et al. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? J Hypertens (2007) 25:2117-24. doi:10.1097/HJH.0b013e32829baae7
39. Poole L, Dickens C, Steptoe A. The puzzle of depression and acute coronary syndrome: reviewing the role of acute inflammation. J Psychosom Res (2011) 71:61-8. doi:10.1016/j.jpsychores.2010.12.009
40. Joynt KE, Whellan DJ, O'Connor CM. Depression and cardiovascular disease: mechanisms of interaction. Biol Psychiatry (2003) 54:248-61. doi:10.1016/S0006-3223(03)00568-7
41. Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med (2005) 165:2508-13. doi:10.1001/archinte.165.21.2508
42. Mayou RA, Gill D, Thompson DR, Day A, Hicks N, Volmink J, et al. Depression and anxiety as predictors of outcome after myocardial infarction. Psychosom Med (2000) 62:212-9. doi:10.1097/00006842-200003000-00011
43. Lane D, Carroll D, Ring C, Beevers DG, Lip GY. Mortality and quality of life 12 months after myocardial infarction: effects of depression and anxiety. Psychosom Med (2001) 63:221-30. doi:10.1097/00006842-200103000-00005
44. Kronish IM, Rieckmann N, Halm EA, Shimbo D, Vorchheimer D, Haas DC, et al. Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes. J Gen Intern Med (2006) 21:1178-83. doi:10.1111/j.1525-1497.2006.00586.x
45. Lane D, Carroll D, Ring C, Beevers DG, Lip GY. Predictors of attendance at cardiac rehabilitation after myocardial infarction. J Psychosom Res (2001) 51:497-501. doi:10.1016/S0022-3999(01)00225-2
46. Swardfager W, Herrmann N, Marzolini S, Saleem M, Farber SB, Kiss A, et al. Major depressive disorder predicts completion, adherence, and outcomes in cardiac rehabilitation: a prospective cohort study of 195 patients with coronary artery disease. J Clin Psychiatry (2011) 72:1181. doi:10.4088/JCP.09m05810blu
47. John U, Meyer C, Rumpf H-J, Hapke U. Self-efficacy to refrain from smoking predicted by major depression and nicotine dependence. Addict Behav (2004) 29:857-66. doi:10.1016/j.addbeh.2004.02.053
48. Malzberg B. Mortality among patients with involution melancholia. Am J Psychiatry (1937) 93:1231-8. doi:10.1176/ajp.93.5.1231
49. Steinberg JS, Arshad A, Kowalski M, Kukar A, Suma V, Vloka M, et al. Increased incidence of life-threatening ventricular arrhythmias in implantable defibrillator patients after the World Trade Center attack. J Am Coll Cardiol (2004) 44:1261-4. doi:10.1016/j.jacc.2004.06.032
50. Leor J, Poole WK, Kloner RA. Sudden cardiac death triggered by an earthquake. N Engl J Med (1996) 334:413-9. doi:10.1056/NEJM199602153340701
51. Wilbert-Lampen U, Leistner D, Greven S, Pohl T, Sper S, Völker C, et al. Cardiovascular events during World Cup soccer. N Engl J Med (2008) 358:475-83. doi:10.1056/NEJMoa0707427
52. Esler M, Jennings G, Lambert G. Measurement of overall and cardiac norepinephrine release into plasma during cognitive challenge. Psychoneuroendocrinology (1989) 14:477-81. doi:10.1016/0306-4530(89)90047-4
53. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol (1995) 26:1257-63. doi:10.1016/0735-1097(95)00332-0
54. L'Abbate A, Simonetti I, Carpeggiani C, Michelassi C. Coronary dynamics and mental arithmetic stress in humans. Circulation (1991) 83:II94-9.
55. Barton DA, Esler MD, Dawood T, Lambert EA, Haikerwal D, Brenchley C, et al. Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy. Arch Gen Psychiatry (2008) 65:38-46. doi:10.1001/archgenpsychiatry.2007.11
56. Otte C, Mccaffery J, Ali S, Whooley MA. Association of a serotonin transporter polymorphism (5-HTTLPR) with depression, perceived stress, and norepinephrine in patients with coronary disease: the Heart and Soul Study. Am J Psychiatry (2007) 164:1379-84. doi:10.1176/appi.ajp.2007.06101617
57. Gold PW, Wong M-L, Goldstein DS, Gold HK, Ronsaville DS, Esler M, et al. Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia. Proc Natl Acad Sci U S A (2005) 102:8303-8. doi:10.1073/pnas.0503069102
58. Lambert EA, Schlaich MP. Reduced sympathoneural responses to the cold pressor test in individuals with essential hypertension and in those genetically predisposed to hypertension.*No support for the "pressor reactor" hypothesis of hypertension development. Am J Hypertens (2004) 17:863-8. doi:10.1016/S0895-7061(04)00844-1
59. Guzzetti S, Piccaluga E, Casati R, Cerutti S, Lombardi F, Pagani M, et al. Sympathetic predominance an essential hypertension: a study employing spectral analysis of heart rate variability. J Hypertens (1988) 6:711-7. doi:10.1097/00004872-198809000-00004
60. Krittayaphong R, Cascio WE, Light KC, Sheffield D, Golden RN, Finkel JB, et al. Heart rate variability in patients with coronary artery disease: differences in patients with higher and lower depression scores. Psychosom Med (1997) 59:231-5. doi:10.1097/00006842-199705000-00004
61. Carney RM, Freedland KE, Stein PK, Skala JA, Hoffman P, Jaffe AS. Change in heart rate and heart rate variability during treatment for depression in patients with coronary heart disease. Psychosom Med (2000) 62:639-47. doi:10.1097/00006842-200009000-00007
62. Pitzalis MV, Iacoviello M, Todarello O, Fioretti A, Guida P, Massari F, et al. Depression but not anxiety influences the autonomic control of heart rate after myocardial infarction. Am Heart J (2001) 141:765-71. doi:10.1067/mhj.2001.114806
63. Kleiger RE, Miller JP, Bigger JT, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol (1987) 59:256-62. doi:10.1016/0002-9149(87)90795-8
64. Bigger JT, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation (1992) 85:164-71. doi:10.1161/01.CIR.85.1.164
65. La Rovere MT, Bigger JT, Marcus FI, Mortara A, Schwartz PJ, Investigators A. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet (1998) 351:478-84. doi:10.1016/S0140-6736(97)11144-8
66. Walther T, Wessel N, Baumert M, Stepan H, Voss A, Faber R. Longitudinal analysis of heart rate variability in chronic hypertensive pregnancy. Hypertens Res (2005) 28:113-8. doi:10.1291/hypres.28.113
67. Gold P, Chrousos G. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs. low CRH/NE states. Mol Psychiatry (2002) 7:254-75. doi:10.1038/sj.mp.4001032
68. Parker KJ, Schatzberg AF, Lyons DM. Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav (2003) 43:60-6. doi:10.1016/S0018-506X(02)00016-8
69. Björntorp P. Neuroendocrine abnormalities in human obesity. Metabolism (1995) 44:38-41. doi:10.1016/0026-0495(95)90208-2
70. Björntorp P, Rosmond R. The metabolic syndrome - a neuroendocrine disorder? Br J Nutr (2000) 83:S49-57. doi:10.1017/S0007114500000957
71. Björntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity. Int. J Obes Relat Metab Disord (2000) 24:S80-5. doi:10.1038/sj.ijo.0801285
72. Malik S, Wong ND, Franklin SS, Kamath TV, Gilbert J, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation (2004) 110:1245-50. doi:10.1161/01.CIR.0000140677.20606.0E
73. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes (1992) 41:715-22. doi:10.2337/diabetes.41.6.715
74. Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestel PJ. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab (2005) 90:5998-6005. doi:10.1210/jc.2005-0961
75. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol (2004) 44:671-719. doi:10.1161/01.CIR.0000134791.68010.FA
76. Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord (1995) 34:301-9. doi:10.1016/0165-0327(95)00028-L
77. Lerman A, Zeiher AM. Endothelial function cardiac events. Circulation (2005) 111:363-8. doi:10.1161/01.CIR.0000153339.27064.14
78. Chauvet-Gélinier J-C, Trojak B, Vergès-Patois B, Cottin Y, Bonin B. Review on depression and coronary heart disease. Arch Cardiovasc Dis (2013) 106:103-10. doi:10.1016/j.acvd.2012.12.004
79. Nemeroff CB, Musselman DL. Are platelets the link between depression and ischemic heart disease? Am Heart J (2000) 140:S57-62. doi:10.1067/mhj.2000.109978
80. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and ß-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry (1997) 42:290-5. doi:10.1016/S0006-3223(96)00345-9
81. Sanner JE, Frazier L. The role of serotonin in depression and clotting in the coronary artery disease population. J Cardiovasc Nurs (2011) 26:423-9. doi:10.1097/JCN.0b013e3182076a81
82. Frasure-Smith N, Lespérance F. Reflections on depression as a cardiac risk factor. Psychosom Med (2005) 67:S19-25. doi:10.1097/01.psy.0000162253.07959.db
83. Maes M, Vandoolaeghe E, Ranjan R, Bosmans E, Bergmans R, Desnyder R. Increased serum interleukin-1-receptor-antagonist concentrations in major depression. J Affect Disord (1995) 36:29-36. doi:10.1016/0165-0327(95)00049-6
84. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol (2002) 90:1279-83. doi:10.1016/S0002-9149(02)02863-1
85. Alesci S, Martinez PE, Kelkar S, Ilias I, Ronsaville DS, Listwak SJ, et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab (2005) 90:2522-30. doi:10.1210/jc.2004-1667
86. Leo R, Di Lorenzo G, Tesauro M, Razzini C, Forleo GB, Chiricolo G, et al. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry (2006) 67:1760-6. doi:10.4088/JCP.v67n1114
87. Dawood T, Lambert EA, Barton DA, Laude D, Elghozi J, Esler MD, et al. Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk. Hypertens Res (2007) 30:285. doi:10.1291/hypres.30.285
88. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet (1997) 350:430-6. doi:10.1016/S0140-6736(97)03079-1
89. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation (2003) 108:2993-9. doi:10.1161/01.CIR.0000104566.10178.AF
90. Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, et al. Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med (2006) 21:30-8. doi:10.1111/j.1525-1497.2005.00269.x
91. Whooley MA. Depression and cardiovascular disease: healing the broken-hearted. JAMA (2006) 295:2874-81. doi:10.1001/jama.295.24.2874
92. Coloquin D, Bunker S, Clarke D, Glozier N, Hare D, Hickie I. Screening, referral and treatment of depression in patients with coronary heart disease. A consensus statement from the National Heart Foundation of Australia. Med J Aust (2013) 198:483-4. doi:10.5694/mja13.10153
93. Davidson KW. Depression and coronary heart disease. ISRN Cardiol (2012) 2012. doi:10.5402/2012/743813
94. Hare DL, Davis CR. Cardiac depression scale: validation of a new depression scale for cardiac patients. J Psychosom Res (1996) 40:379-86. doi:10.1016/0022-3999(95)00612-5
95. Dickens C, Mcgowan L, Percival C, Tomenson B, Cotter L, Heagerty A, et al. New onset depression following myocardial infarction predicts cardiac mortality. Psychosom Med (2008) 70:450-5. doi:10.1097/PSY.0b013e31816a74de
96. Cohen BE, Edmondson D, Kronish IM. State of the art review: depression, stress, anxiety, and cardiovascular disease. Am J Hypertens (2015) 28(11):1295-302. doi:10.1093/ajh/hpv047
97. Mazza M, Lotrionte M, Biondi-Zoccai G, Abbate A, Sheiban I, Romagnoli E. Selective serotonin reuptake inhibitors provide significant lower re-hospitalization rates in patients recovering from acute coronary syndromes: evidence from a meta-analysis. J Psychopharmacol (2010) 24:1785-92. doi:10.1177/0269881109348176
98. Tata L, West J, Smith C, Farrington P, Card T, Smeeth L, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart (2005) 91:465-71. doi:10.1136/hrt.2004.037457
99. Zellweger MJ, Osterwalder RH, Langewitz W, Pfisterer ME. Coronary artery disease and depression. Eur Heart J (2004) 25:3-9. doi:10.1016/j.ehj.2003.09.009
100. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev (2011) 9:CD008012. doi:10.1002/14651858.CD008012.pub3
101. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, Van Zyl LT, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation (2003) 108:939-44. doi:10.1161/01.CIR.0000085163.21752.0A
102. ENRICHD Investigators. Enhancing Recovery in Coronary Heart Disease (ENRICHD) study intervention: rationale and design. Psychosom Med (2001) 63:747-55.
103. Skala JA, Freedland KE, Carney RM. Coronary heart disease and depression: a review of recent mechanistic research. Can J psychiatry (2006) 51:738.
104. Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, et al. Depression, heart rate variability, and acute myocardial infarction. Circulation (2001) 104:2024-8. doi:10.1161/hc4201.097834
105. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry (2000) 61:863-7. doi:10.4088/JCP.v61n1109
106. Raeder MB, Bjelland I, Emil VS, Steen VM. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J Clin Psychiatry (2006) 67:1974-82. doi:10.4088/JCP.v67n1219
107. Dannon PN, Iancu I, Cohen A, Lowengrub K, Grunhaus L, Kotler M. Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry (2004) 4:16. doi:10.1186/1471-244X-4-16
108. Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry (2004) 65:1365-71. doi:10.4088/JCP.v65n1011
109. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med (2005) 142:532-46. doi:10.7326/0003-4819-142-7-200504050-00012
110. Pilling S, Anderson I, Goldberg D, Meader N, Taylor C. Depression in adults, including those with a chronic physical health problem: summary of NICE guidance. BMJ (2009) 339. doi:10.1136/bmj.b4108
111. Lichtman JH, Bigger JT, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lespérance F, et al. Depression and coronary heart disease recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation (2008) 118:1768-75. doi:10.1161/CIRCULATIONAHA.108.190769
112. Hamer M, Batty GD, Seldenrijk A, Kivimaki M. Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. Eur Heart J (2011) 32:437-42. doi:10.1093/eurheartj/ehq438
113. Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol (2003) 23:58-77. doi:10.1097/00004714-200302000-00010
114. Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr Scand (2008) 118:434-42. doi:10.1111/j.1600-0447.2008.01260.x
115. Follath F. [Depression, stress and coronary heart disease - epidemiology, prognosis and therapeutic sequelae]. Ther Umsch (2003) 60:697-701. doi:10.1024/0040-5930.60.11.697
116. Whalley B, Rees K, Davies P, Bennett P, Ebrahim S, Liu Z, et al. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev (2011) 21:8. doi:10.1002/14651858.CD002902.pub3
117. Cooney GM, Dwan K, Greig CA, Lawlor DA, Rimer J, Waugh FR, et al. Exercise for depression. Cochrane Database Syst Rev (2013) 9:CD004366. doi:10.1002/14651858.CD004366.pub6
118. Dauwan M, Begemann MJ, Heringa SM, Sommer IE. Exercise improves clinical symptoms, quality of life, global functioning, and depression in schizophrenia: a systematic review and meta-analysis. Schizophr Bull (2015) sbv164. doi:10.1093/schbul/sbv164
119. Milani RV, Lavie CJ, Cassidy MM. Effects of cardiac rehabilitation and exercise training programs on depression in patients after major coronary events. Am Heart J (1996) 132:726-32. doi:10.1016/S0002-8703(96)90304-X
120. Musselman DL, Marzec UM, Manatunga A, Penna S, Reemsnyder A, Knight BT, et al. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry (2000) 57:875-82. doi:10.1001/archpsyc.57.9.875
121. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol (2000) 20:137-40. doi:10.1097/00004714-200004000-00004